Louis W. Sullivan net worth and biography

Louis Sullivan Biography and Net Worth

Director of United Therapeutics

Dr. Sullivan has served as a director since June 2006. Dr. Sullivan has served as president emeritus of Morehouse School of Medicine since July 2002. Dr. Sullivan served as president of Morehouse School of Medicine from 1981 to 1989 and from 1993 to 2002. From 1989 to 1993, Dr. Sullivan was Secretary of the Department of Health and Human Services. Dr. Sullivan serves on the boards of directors of United Therapeutics Corporation, BioSante Pharmaceuticals and Henry Schein, Inc., all publicly held biotechnology companies. He was a founder and chairman of Medical Education for South African Blacks, Inc., a trustee of Africare, a director of the National Center on Addiction and Substance Abuse at Columbia University and chairman of the board of trustees of the National Health Museum, a non-profit institution developing a museum of health sciences. Dr. Sullivan received his M.D. from Boston University and a B.S. from Morehouse College.

What is Louis W. Sullivan's net worth?: The estimated net worth of Louis W. Sullivan is at least $1.82 million as of December 18th, 2024. Dr. Sullivan owns 5,051 shares of United Therapeutics stock worth more than $1,816,239 as of December 21st. This net worth estimate does not reflect any other investments that Dr. Sullivan may own. Learn More about Louis W. Sullivan's net worth.
How do I contact Louis W. Sullivan?: The corporate mailing address for Dr. Sullivan and other United Therapeutics executives is 1040 SPRING ST, SILVER SPRING MD, 20910. United Therapeutics can also be reached via phone at (301) 608-9292 and via email at [email protected]. Learn More on Louis W. Sullivan's contact information.
Has Louis W. Sullivan been buying or selling shares of United Therapeutics?: In the last ninety days, Louis W. Sullivan has sold $9,781,722.98 in shares of United Therapeutics stock. Most recently, Louis W. Sullivan sold 26,209 shares of the business's stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $373.22, for a transaction totalling $9,781,722.98. Following the completion of the sale, the director now directly owns 5,051 shares of the company's stock, valued at $1,885,134.22. Learn More on Louis W. Sullivan's trading history.
Who are United Therapeutics' active insiders?: United Therapeutics' insider roster includes Michael Benkowitz (COO), Christopher Causey (Director), Raymond Dwek (Director), James Edgemond (CFO), Paul Mahon (EVP), Nilda Mesa (Director), Judy Olian (Director), Christopher Patusky (Director), Martine Rothblatt (CEO), and Louis Sullivan (Director). Learn More on United Therapeutics' active insiders.
Are insiders buying or selling shares of United Therapeutics?: During the last twelve months, insiders at the biotechnology company sold shares 80 times. They sold a total of 472,479 shares worth more than $143,828,624.02. The most recent insider tranaction occured on December, 18th when Director Louis W Sullivan sold 26,209 shares worth more than $9,781,722.98. Insiders at United Therapeutics own 11.9% of the company. Learn More about insider trades at United Therapeutics.
Information on this page was last updated on 12/18/2024.

Louis W. Sullivan Insider Trading History at United Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/18/2024	Sell	26,209	$373.22	$9,781,722.98	5,051
2/1/2023	Sell	700	$261.33	$182,931.00	12,180
1/3/2023	Sell	700	$276.26	$193,382.00	12,180
12/1/2022	Sell	700	$279.89	$195,923.00	12,180
11/1/2022	Sell	700	$230.28	$161,196.00	12,180
10/3/2022	Sell	710	$211.56	$150,207.60	12,180
6/18/2015	Sell	15,000	$185.60	$2,784,000.00

Louis W. Sullivan Buying and Selling Activity at United Therapeutics

United Therapeutics Company Overview

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Today's Range

Now: $359.58

$357.98

$363.90

50 Day Range

MA: $371.01

$348.65

$410.00

2 Week Range

Now: $359.58

$208.62

$417.82

Volume

1,009,218 shs

Average Volume

449,066 shs

Market Capitalization

$16.05 billion

P/E Ratio

15.79

Dividend Yield

N/A

Beta

0.54

From Behind the Markets | Ad

My research indicates there is only one investment that can meet AI's unprecedented demand for energy.

Click to get the name and ticker symbol